Literature DB >> 9446652

Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4.

J S Suh1, R H Aster, G P Visentin.   

Abstract

Antibodies associated with heparin-induced thrombocytopenia/ thrombosis (HITT) are now thought to be specific for complexes formed between heparin and platelet factor 4 (PF4), a basic protein found normally in platelet alpha granules. How these antibodies cause thrombocytopenia and, in some patients, thrombosis, is not fully understood, in part because purified antibodies that could be labeled and used as probes to characterize target epitopes have not been available. We developed a novel method for antibody purification involving binding to and elution from PF4 complexed to heparin immobilized by end-linkage (EL) to a solid phase. Isolated antibodies were functional and after biotinylation, reacted with heparin: PF4 complexes in the same manner as unlabeled antibodies. Using these probes, we found that antibodies from 11 patients with HITT recognized two, and probably three, distinct sites on heparin: PF4 complexes. The antibodies did not bind to PF4 complexed with heparin immobilized by multiple chemical cross-linkages, suggesting that the heparin molecule must be in a flexible, relatively unconstrained state to react with PF4 in such a way as to create sites for HITT antibody binding.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9446652

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Fundamental concepts in the pathobiology of heparin-induced thrombocytopenia.

Authors:  J L Januzzi; I K Jang
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

Review 2.  [Cardiopulmonary bypass in cardiac surgery].

Authors:  T Baehner; O Boehm; C Probst; B Poetzsch; A Hoeft; G Baumgarten; P Knuefermann
Journal:  Anaesthesist       Date:  2012-10       Impact factor: 1.041

3.  Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia.

Authors:  Valerie Tutwiler; Daria Madeeva; Hyun Sook Ahn; Izabella Andrianova; Vincent Hayes; X Long Zheng; Douglas B Cines; Steven E McKenzie; Mortimer Poncz; Lubica Rauova
Journal:  Blood       Date:  2015-10-30       Impact factor: 22.113

4.  Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis.

Authors:  Anand Padmanabhan; Curtis G Jones; Daniel W Bougie; Brian R Curtis; Janice G McFarland; Demin Wang; Richard H Aster
Journal:  Blood       Date:  2014-10-23       Impact factor: 22.113

5.  Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT.

Authors:  M Anna Kowalska; Sriram Krishnaswamy; Lubica Rauova; Li Zhai; Vincent Hayes; Karine Amirikian; Jeffrey D Esko; Daniel W Bougie; Richard H Aster; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

6.  Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.

Authors:  Theodore E Warkentin; Richard J Cook; Victor J Marder; Jo-Ann I Sheppard; Jane C Moore; Bengt I Eriksson; Andreas Greinacher; John G Kelton
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

7.  Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion.

Authors:  Zhihua Xiao; Gian P Visentin; Kannayakanahalli M Dayananda; Sriram Neelamegham
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

8.  Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway.

Authors:  Sanjay Khandelwal; Joann Ravi; Lubica Rauova; Alexandra Johnson; Grace M Lee; Jennifer B Gilner; Sreenivasulu Gunti; Abner L Notkins; Maragatha Kuchibhatla; Michael Frank; Mortimer Poncz; Douglas B Cines; Gowthami M Arepally
Journal:  Blood       Date:  2018-10-11       Impact factor: 25.476

Review 9.  Challenges in Detecting Clinically Relevant Heparin-Induced Thrombocytopenia Antibodies.

Authors:  Theodore E Warkentin
Journal:  Hamostaseologie       Date:  2020-10-22       Impact factor: 1.778

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.